Trial Profile
SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma [SUTNET Trial: Studio Clinico-Biologico Di Fase II Con Sunitinib In Pazienti Affetti Da Feocromocitomi/Paragangliomi In Stadio Avanzato e/o Non Resecabile]
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2013
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Paraganglioma; Phaeochromocytoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms SUTNET
- 10 Oct 2013 New trial record